- Home
- IDYA vs ALEX Comparison
IDYA vs ALEX Comparison
Compare IDYA & ALEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- ALEX
- Stock Information
- Founded
- IDYA 2015
- ALEX 1870
- Country
- IDYA United States
- ALEX United States
- Employees
- IDYA N/A
- ALEX N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- ALEX Real Estate Investment Trusts
- Sector
- IDYA Health Care
- ALEX Real Estate
- Exchange
- IDYA Nasdaq
- ALEX Nasdaq
- Market Cap
- IDYA 1.5B
- ALEX 1.3B
- IPO Year
- IDYA 2019
- ALEX N/A
- Fundamental
- Price
- IDYA $17.42
- ALEX $17.51
- Analyst Decision
- IDYA Strong Buy
- ALEX Buy
- Analyst Count
- IDYA 13
- ALEX 3
- Target Price
- IDYA $53.58
- ALEX $23.00
- AVG Volume (30 Days)
- IDYA 1.4M
- ALEX 464.5K
- Earning Date
- IDYA 05-06-2025
- ALEX 04-24-2025
- Dividend Yield
- IDYA N/A
- ALEX 5.14%
- EPS Growth
- IDYA N/A
- ALEX 38.72
- EPS
- IDYA N/A
- ALEX 0.85
- Revenue
- IDYA $7,000,000.00
- ALEX $236,060,000.00
- Revenue This Year
- IDYA $121.20
- ALEX N/A
- Revenue Next Year
- IDYA $302.20
- ALEX $2.81
- P/E Ratio
- IDYA N/A
- ALEX $20.66
- Revenue Growth
- IDYA N/A
- ALEX 6.41
- 52 Week Low
- IDYA $13.45
- ALEX $15.70
- 52 Week High
- IDYA $44.42
- ALEX $20.30
- Technical
- Relative Strength Index (RSI)
- IDYA 43.87
- ALEX 60.05
- Support Level
- IDYA $16.82
- ALEX $17.17
- Resistance Level
- IDYA $21.43
- ALEX $17.60
- Average True Range (ATR)
- IDYA 1.16
- ALEX 0.37
- MACD
- IDYA -0.16
- ALEX 0.10
- Stochastic Oscillator
- IDYA 13.02
- ALEX 93.99
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About ALEX Alexander & Baldwin Inc. REIT Holding Company
Alexander & Baldwin Inc is a Hawaii commercial real estate company. The group owns, operates, and manages million square feet of retail, industrial, and office space in Hawaii. It is a real estate investment trust (REIT) and the owner of grocery and drug-anchored retail centers in the state. It functions through two segments namely Commercial Real Estate and Land Operations. The Commercial Real Estate segment owns and manages retail, industrial spaces, and also urban ground leases in Hawaii, thereby accounting for a majority of the company's revenue. The Land Operations segment actively manages the company's land and real estate-related assets and makes optimum utilization of these assets. Geographically, the activities are carried out across the United States.